Background
Plant extracts are commonly used in formulations of alternative and traditional medicine such as skin lotions, or when used as ingredients in dietary treatments and teas [
1]. Plant-based medications are well-accepted by patients and are often preferred over chemically produced therapeutics because of their well-known health-benefitting bio-active ingredients [
2‐
6]. Moreover, plant-extractable compounds have also gained a lot of attention in conventional medicine. For instance, plant-based drugs are now used for therapeutic treatment of diseases such as cancer and various inflammatory disorders [
7,
8]. Therefore, knowing and assessing the potentials of plant-derived bio-active compounds is important for further drug development. This notion is deducible from the increasing interest of the pharmaceutical industry in gaining the rights to identify and exploit plant-borne compounds from species-rich rainforests in countries of tropical and subtropical regions [
9‐
11]. While there is certainly a great potential in identifying plant-derived medication, the challenges associated with this venture must also be noted. Some of the current discussion revolving around this topic are: the protection of bio-diversity, acceptance of intellectual property rights, as well as biosafety of application [
12,
13]. The aim of this study is to establish and provide an experimental, cell biological platform that allows for the identification of plant species that should be characterized and assessed in more detail.
So far, roughly 6 % of all higher plant species existing worldwide have been, or are currently being, assessed for their medicinal potential. In fact, only a minor proportion of these plant species have actually been subjected to detailed phytochemical profiling [
14‐
16]. Bio-active compounds must first be purified before they can be assessed and eventually tested in clinical trials. Of course, the overall aim of the tests would be to ensure the efficacy of the biomolecules in particular therapeutic approaches. Simultaneously, drug safety and absence of undesirable side-effects are of the highest concern [
17]. These considerations are important, regardless of whether pure compounds or crude extracts of an entire plant, or parts thereof, are used for the production of a pharmaceutically applicable plant ingredient [
18].
The genus
Rhododendron, comprising the species-richest group of wooden plants, belongs to the family
Ericaceae and encompasses about one thousand species: the majority of which are indigenous to Asia [
19]. In ethno-medicine, extracts of
Rhododendron have been used traditionally in treating various disorders such as inflammatory conditions, common symptoms of cold, gastrointestinal disorders, skin diseases, or as pain killers [
20]. Recent research highlighted that
Rhododendron leaf extracts might be highly potent and beneficial to health due to properties they contain, such as anti-bacterial [
21,
22], anti-allergic, and anti-inflammatory [
23,
24] agents. The reported usefulness of crude extracts of
R. ferrugineum and
R. anthopogon [
20,
25‐
27] is most likely due to the presence of terpenoids in high concentrations [
25].
Previously, we investigated leaf extracts of 120 different
Rhododendron species for their efficacy as antimicrobials in killing a variety of Gram-positive and Gram-negative bacteria [
25]. In the current study, extracts of 12 of the
Rhododendron species with highest anti-bacterial potencies were applied in different concentrations to monolayer cultures of human HaCaT epidermal keratinocytes and rat intestine epithelial cell line IEC6. Intestinal epithelial cells and keratinocytes are considered to be among the first points of contact when drugs are administered orally or applied ectopically, respectively. In general, bio-active compounds are considered cytotoxic when they alter cellular morphology or metabolism, interfere with the cytoskeleton or cell adhesion, affect cell proliferation rates or cell differentiation processes, or initiate programmed cell death [
28]. Different cell types might exhibit differential responses towards a specific compound or plant extract. Consequently, it is neither sufficient to use only one cell line nor to apply just a single cytotoxicity assay in any safety assessment study.
The aim of this study was to assess possible cytotoxic effects of antimicrobial Rhododendron leaf extracts on mammalian cells in order to identify a potential candidate species for further analysis of safe use. Thus, the study contributes to on-going investigations on the bioactivity potential of plant species such as the Rhododendron. Hence, the effects of Rhododendron leaf extracts on cell survival, metabolism, and growth as well as on different cellular structures were monitored in vitro by an array of cell biological assays employing differentiated cell lines.
Methods
Collection of plant material and leaf extract preparation
Fresh leaf material of reliably identified
Rhododendron species was used in this study (Table
1). The material was collected from January 2012 to December 2013 from plants grown in the Rhododendron-Park Bremen (
www.rhododendronparkbremen.de). Each plant species was sampled once without considering seasonal variations. The identities of the plant species used in this study (Table
1) have been verified by reference to the German Gene Bank Rhododendron Database provided by the
Bundessortenamt (
www.bundessortenamt.de/rhodo) [
25]. Material from all plant species used is publicly and freely available from the Rhododendron-Park Bremen upon request.
Table 1
List of Rhododendron species from which leaves were collected and used to prepare extracts that were screened for exhibiting cytotoxicity towards intestine epithelial cell cultures and monolayers of keratinocytes
100.345 |
R. ferrugineum L. | Rhododendron | Rhododendron |
100.007 |
R. ambiguum Hemsley | Rhododendron | Triflora |
NA |
R. anthopogon Don ssp. anthopogon Betty Graham | Pogonanthum | - |
NA |
R. hirsutum L. | Rhododendron | Rhododendron |
100.326 |
R. concinnum Hemsley | Rhododendron | Triflora |
100.322 |
R. cinnabarinum Hooker | Rhododendron | Cinnabarina |
NA |
R. racemosum Franchet | Rhododendron | Scabrifolia |
100.404 |
R. rubiginosum Franchet | Rhododendron | Heliolepida |
100.474 |
R. xanthostephanum Merrill | Rhododendron | Tephropepla |
100.370 |
R. minus Michaux | Rhododendron | Caroliniana |
100.392 |
R. polycladum Franchet | Rhododendron | Lapponica |
100.353 |
R. hippophaeoides var. hippophaeoides Hutchinson | Rhododendron | Lapponica |
Leaf material was frozen in liquid nitrogen and powdered using a KSW 3307 mill (Clatronic, Kempen, Germany). Crude extracts were prepared by soaking two grams of Rhododendron leaf powder in 10 mL of 80 % methanol for 24 h at 4 °C with constant shaking. Insoluble material was removed by centrifugation at 3,220 g for 30 min at 4 °C, and supernatants were stored at -20 °C for further use. Methanol was evaporated from the extracts using a Micro Modulyo lyophilizer (Edwards, Crawley, UK). Stock solutions were prepared by dissolving the residues in 100 % dimethyl sulfoxide (DMSO) (Carl Roth, Karlsruhe, Germany). Prior to the in vitro assays, the samples were mixed with the respective cell culture medium such that the final concentration of DMSO did not exceed 0.5 % (v/v), and 5, 50, or 500 μg of lyophilized powder per mL culture medium were applied to confluent IEC6 and HaCaT cell monolayers.
Cell culture
The normal rat small intestine epithelial cell line IEC6 [
29,
30] and the human keratinocyte cell line HaCaT [
31,
32], purchased from the European Collection of Cell Cultures (Salisbury, UK), were used throughout this study. IEC6 cells were grown in Dulbecco’s modified Eagle’s Medium (DMEM High Glucose) (Lonza Group, Basel, Switzerland) supplemented with 10 % fetal calf serum (FCS) (Perbio Science, Bonn, Germany) and 10 μg/mL insulin (Sigma-Aldrich, Steinheim, Germany). IEC6 cells were incubated at 37 °C in a 5 % CO
2 atmosphere in an incubator (Heraeus, Osterode, Germany). HaCaT cells were cultured in DMEM containing 10 % FCS and incubated at 37 °C in an 8.4 % CO
2 atmosphere. Cell cultures were passaged once per week. All experiments were performed with cultures at approx. 70 % and 95 % confluence for IEC6 and HaCaT cells, respectively.
Determination of cell viability and proliferative activity by MTT assays
Effects of
Rhododendron leaf extracts on the viability and proliferative activity of cultured IEC6 and HaCaT cells were quantitated using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay (Carl Roth). This test is indicative for mitochondrial NADH-dependent dehydrogenase activity, which is proportional to both cell viability and proliferation rates of treated cultures [
33‐
35]. A total of 1 × 10
4 cells/well were seeded in single wells of 96-well plates (Greiner, Essen, Germany) and upon reaching the desired confluence, the cells were incubated with three different concentrations of
Rhododendron leaf extracts (5, 50, and 500 μg per mL culture medium, not exceeding 0.5 % DMSO in content) for 24 h in complete medium and at standard culture conditions. Incubation of cells with culture medium containing DMSO at a final concentration of 0.5 % (v/v) was used as a negative control. Culture supernatants containing free-floating dead cells were removed at the end of the incubation period, replaced with fresh culture medium containing MTT at a final concentration of 0.5 % (w/v). The cell layers were then further incubated for another four hours. Subsequently, culture supernatants were removed, the cells adherent to the plate surface were collected in 100 % DMSO and incubated for 15 min at 37 °C to terminate the reaction and to dissolve formazan crystals. The absorbance of formazan formed by
Rhododendron leaf extract-treated and non-treated control cell cultures was quantified at 595 nm in a microplate reader against the solvent (Tecan Group, Männedorf, Switzerland). Percentages of cell viability were calculated from triplicates using Eq. (
1):
$$ \%\kern0.5em of\kern0.5em cell\kern0.5em viability=\left(\frac{absorbance\kern0.5em of\kern0.5em treated\; cell s}{absorbance\kern0.5em of\kern0.5em control\kern0.5em cell s}\right)\times 100 $$
(1)
Propidium iodide staining of nuclei in cells with ruptured plasma membranes
The two cell lines were grown on cover glasses in 24-well Bio-One Cellstar plates (Greiner) to reach the desired degree of confluence. Next, cells were incubated with three different concentrations of
Rhododendron leaf extracts (i.e. 5, 50, or 500 μg/mL) for 24 h as described above. Subsequently, cells were washed three times with phosphate-buffered saline (PBS) before being incubated for 45 min in 2 mg/mL propidium iodide (PI) (Carl Roth) and 5 μM Draq5™ (Biostatus, Leicester, UK) in culture medium at 37 °C. After washing three times in PBS, cells were fixed in 4 % paraformaldehyde (PFA) (Carl Roth) in 200 mM HEPES (pH 7.4) at room temperature for 20 min. Cells on cover glasses were washed again in PBS and distilled water before mounting them in Mowiol for subsequent laser scanning microscopy as described previously [
36]. PI is not capable of penetrating cells with intact plasma membranes, however, if plasma membrane integrity is lost, PI gains access to the nucleus and forms complexes with the DNA. In contrast, Draq5™ serves as a nuclear counter-stain that transverses the intact plasma membrane and can therefore be used to determine the total cell number. Special care had to be taken when analyzing total cell numbers, because some plant leaf extracts could have exhibited anti-adhesive effects such that total cell numbers were significantly diminished after washing steps. Therefore, total cell numbers were determined and reported herein as a measure for anti-adhesive properties of
Rhododendron-derived compounds.
Phalloidin staining of the filamentous actin cytoskeleton
IEC6 and HaCaT cells were grown on cover glasses in 24-well plates to reach 70 % and 95 % confluence, respectively, and exposed to Rhododendron leaf extracts for 24 h as described above, while 0.5 % DMSO was used as a negative control. Cells were washed three times with PBS before fixation in 4 % PFA in 200 mM HEPES (pH 7.4) at room temperature for 20 min. After fixation, cells were washed with PBS before applying 0.2 % Triton X-100 in PBS for 5 min at room temperature, followed by several washing steps in PBS. Finally, cells were stained for 30 min at room temperature with a mixture of 3 μM FITC-labeled phalloidin (Sigma Aldrich) and 5 μM Draq5™ in PBS, the latter used as a counter-stain of nuclear DNA. Cover glasses were mounted in Mowiol for subsequent inspection by laser scanning microscopy (see below).
MitoTracker® Red CMXRos staining of the mitochondrial matrix
Cells were incubated and treated as described above, before washing twice in phenol red-free HEPES-buffered culture medium for 5 min. Subsequently, the cells were incubated with phenol red-free culture medium containing 20 mM HEPES and 500 nM MitoTracker® Red CMXRos (Molecular Probes, Oregon, USA) for 45 min at 37 °C followed by several washes. The fluorescent dye accumulates in the mitochondrial matrix only when an intact membrane potential, due to active cellular metabolism, is present across the inner mitochondrial membrane. Cells were fixed with 4 % PFA in 200 mM HEPES (pH 7.4) for 20 min at room temperature, rinsed, and mounted on microscope slides as described above for subsequent microscopic inspection.
Microscopy techniques
Stained cells were visualized with an LSM 510 confocal laser scanning microscope (Carl Zeiss, Jena, Germany) at excitation wavelengths of 488 nm, 543 nm and 633 nm for fluorophore excitation to visualize FITC-phalloidin, PI or MitoTracker® Red CMXRos, and Draq5™, respectively. Scans at a resolution of 1024 x1024 pixels were taken in the line averaging mode and at a pinhole setting of one airy unit. Color coding and image analysis was performed by using the LSM 510 software, release 3.2 (Carl Zeiss).
Caspase-3 activity assay
For IEC6 cells, induction of apoptosis upon incubation with
R. ferrugineum and
R. cinnabarinum leaf extracts at the highest concentration, i.e. 500 μg/mL, was evaluated at different time intervals ranging from 1 to 24 h. The apoptosis assay was performed using the EnzChek Caspase-3 assay kit (Invitrogen, Karlsruhe, Germany) detecting activation of procaspase-3 and other Asp-Glu-Val-Asp (DEVD)-specific proteases. Lysates of treated IEC6 cells and non-treated controls were prepared according to the manufacturer’s protocol. Following clearance by centrifugation, the samples were incubated with 5 mM Z-DEVD-R110 substrate for 30 min at 4 °C. Lysates of IEC6 cells treated for 4 h at 37 °C with apoptosis-inducing staurosporin (10 mM) (Sigma-Aldrich) were used as positive controls, whereas no treatment or incubation with the solvent served as negative controls. Additionally, staurosporin-treated cells incubated with 1 mM of Ac-DEVD-CHO for 10 min served as a negative control since caspase-3 activity is blocked under these conditions. The extent of procaspase-3 activation was determined by fluorescence of liberated rhodamine upon excitation at 496 nm and reading the emission at 520 nm, using a microplate reader (Tecan Group, Männedorf, Switzerland). The values were normalized to equal amounts of DNA in the pellets after lysis, as determined by the Burton assay [
37].
Determination of minimum inhibitory concentrations
The minimum inhibitory concentration (MIC) was defined as the lowest concentration of
Rhododendron leaf extract that inhibits visible growth of microorganisms after overnight incubation. The MIC was determined by a two-fold dilution assay in Mueller-Hinton broth (MHB) (Becton Dickinson, Heidelberg, Germany). The
Bacillus subtilis strain
S168 was tested against 12
Rhododendron crude extracts (Table
1) [
25]. All tests were performed in triplicates following the National Center for Clinical Laboratory Standards recommendations [
38].
Statistical evaluation
All assays were performed in triplicates and repeated at least three times in independent experiments unless stated otherwise. All data were expressed as means ± standard deviation (SD), as determined by using Origin software (MicroCal Software, Northampton, USA). The profile map shown in Fig.
9 was created using R (RStudio, Boston, USA). Levels of significance were calculated by One-Way ANOVA, and
p < 0.05 was considered statistically significant. CellProfiler software [
39] was used to determine total cell numbers (Draq5™-positive cells)
versus numbers of dead cells (PI-positive cells). This software was also employed to quantify the MitoTracker® Red CMXRos and FITC-phalloidin fluorescence signal intensities as previously described by us [
32].
Discussion
To date, there are only few medicinal formulations on the market that contain compounds derived from
Rhododendron. These comprise ‘Rhomitoxin’ used to treat hypertension, and ‘
Rhododendron cp paste’ used to relieve pain in arthritis [
10]. In addition, only few
in vitro and
in vivo studies with specific
Rhododendron extracts and compounds isolated thereof have been reported that validated plant extracts as being useful in traditional remedies [
20]. Importantly, plants of the genus
Rhododendron are more commonly used as alternative medicine in the geographic regions of their natural habitats, i.e., Nepal, Northeastern India, Western and Central China, or Indonesia [
20]. This may be due to the fact that the precise chemical composition of medicinal formulations is often not very well defined [
40,
41]. However,
Rhododendron plants are known to synthesize a large number of chemical compounds, some of which exhibit attested pharmacological activities [
42‐
45]. Several of these chemical compounds have been identified to belong to the pro-anthocyanidins, polyphenols, or terpenoids which are typically synthesized by plants reacting in defense to pathogenic infection or inflictions caused by herbivores [
46,
47].
Not surprisingly, various plant-derived compounds exert severe cytotoxic or mutagenic effects when applied to animal cells and tissues [
48,
49]. Intoxication of domesticated or wild animals feeding on
Rhododendron plants have been repeatedly reported and were linked to the presence of grayano-toxins [
50‐
52]. Therefore, a comprehensive number of cytotoxicity studies involving mammalian cells or tissue cultures must be conducted before a given extract or a defined Rhododendron-derived compound can eventually be considered for testing on animal models, or even enter clinical trials [
53,
54].
To the best of our knowledge, none of the previous studies had comprehensively analyzed the cytotoxicity of a group of pharmaceutically interesting Rhododendron species. Consequently, the current study introduces a multi-facetted approach, consisting of five different cytotoxicity assays, in order to investigate the effects of Rhododendron leaf extracts on cellular structure, metabolic activity, and viability of two different types of mammalian cells.
The results obtained herein show that treating IEC6 and HaCaT cells with low concentrations of leaf extracts prepared from any of the 12 Rhododendron species exhibited rather mild or no cytotoxic effects, whereas the use of high concentrations (500 μg/mL) resulted in a rather expected and remarkable cytotoxicity. A total of five Rhododendron species exhibited high antibacterial activities with MICs of 50 μg/mL and proved to be non-cytotoxic at this concentration. Interestingly, extracts of R. minus and R. racemosum were non-toxic to either cell lines, which makes them promising candidates for future studies. In contrast, incubation of either of the two cell lines with 500 μg/mL of the other Rhododendron leaf extracts resulted in severe structural and functional alterations often associated with signs of apoptosis. Our study thus confirmed that simultaneous analysis of several, albeit partially unlinked or only indirectly linked cellular parameters, is a convenient tool to separate potentially cytotoxic extracts from their ‘safe-to-use’ Rhododendron extracts counterparts, thus overcoming technical short-comings of previous studies aiming at high-throughput screening.
Our results demonstrated that the incubation of cells with high concentrations of
Rhododendron leaf extracts induced apoptosis specifically in intestine epithelial cells. Interestingly, only two extracts, namely those of
R. cinnabarinum and
R. ferrugineum, shared a similar pattern of cytotoxicity in all assays tested in this study. Leaf extracts of these two
Rhododendron species were capable of inducing procaspase-3 activation prominently in IEC6 cells. The results of this study concur with other studies that have shown several secondary metabolic compounds from
Rhododendron species to induce apoptosis in cultures of different mammalian cell lines [
55,
57].
Overall, keratinocytes were more resistant to cytotoxicity exerted upon incubation with
Rhododendron leaf extracts than IEC6 cells. Resistance of HaCaT cells against cytotoxic agents was observed by us previously when studying dust exposure [
32]. This remarkable feature of keratinocytes might be due to the specific lipid composition of their membranes and their ability to build a stratified epithelium when exposed to air during cornification [
32,
57,
58].
Conclusion
Using a comprehensive approach, the cytotoxicity of those Rhododendron species that had previously been shown to exhibit the highest antibacterial activities was determined. As such, we managed to continue our ongoing approach in identifying pharmaceutically feasible antibiotics or lead structures. Utilizing two tester cell lines as relevant models for the envisioned ectopic or oral treatment and applying several different cell biological assays, proved to be a suitable combination of screening tools. Two out of the 12 Rhododendron species with antibacterial properties exhibit the desired traits: the extracts of R. minus and R. racemosum were both non-cytotoxic at a concentration at where they efficiently produced an inhibition zone for B. subtilis.
Furthermore, we could conclude that Rhododendron leaf extracts induced apoptosis, as evidenced by typical alterations of the cellular phenotypes (chromatin condensation and formation of plasma membrane blebs) as well as by the increasing levels of active caspase-3 when cells were exposed to higher extract concentrations. In the future, we will extend our current study in order to determine whether the specific apoptosis-inducing effects of R. cinnabarinum and R. ferrugineum can be used to selectively target cancer cells, such as colorectal carcinoma cells.
In our future research, we will focus on phyto-chemically identifying the actual active compounds present in the leaf extracts derived from different Rhododendron species. We plan to determine the IC 50 values and to study their potential cytotoxic effects through a repertoire of different methods similar to the cell biological screening tool box laid out in the current study.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
AR designed experiments, conducted the experimental work and the analysis, and contributed to manuscript writing; AH and WJ contributed to the experimental work presented in Figs.
4,
6 and
7; HS collected, identified, and prepared plant material. MU and KBr designed the study, supervised the work, discussed the results, and contributed to manuscript writing. All authors read and approved the final manuscript.